CAMBRIDGE, Mass. & BRISBANE, Australia, December 01, 2022–(BUSINESS WIRE)–Vaxxas, a clinical-stage biotechnology firm commercializing a novel vaccination platform, at the moment introduced one other key addition to its government management workforce with the appointment of Doug Cubbin as Chief Monetary Officer. Doug joins Vaxxas as the corporate experiences vital development and advances towards commercialization of its high-density microarray patch (HD-MAP) vaccine supply know-how.
This press launch options multimedia. View the total launch right here: https://www.businesswire.com/news/home/20221201005409/en/
Vaxxas CFO Doug Cubbin (Picture: Enterprise Wire)
A extremely certified government chief, Doug has greater than 30 years’ expertise in finance, M&A, and enterprise growth. Most lately, Doug was the Group Chief Monetary Officer at Telix Prescription drugs Restricted, a worldwide ASX 200 biopharmaceutical firm targeted on the event and commercialization of diagnostic and therapeutic merchandise.
Throughout his tenure at Telix, Doug helped develop the market capitalization of the enterprise to AU$2.3 billion (US$1.6 billion) and constructed a worldwide finance workforce. He was additionally a key member of the workforce who efficiently accomplished the Telix IPO, and subsequent capital raises, with a complete of AU$270 million (US$180 million) raised. Throughout Doug’s time with Telix, the corporate made 4 acquisitions.
Previous to Telix, Doug held roles of Chief Monetary Officer and Chief Working Officer at ANSTO, Govt Chairman of ANSTO Nuclear Drugs, and Chief Monetary Officer at DHL Oceania and South Pacific.
“It’s been an unimaginable interval of development for Vaxxas and we’re happy to be strengthening our workforce with the appointment of Doug Cubbin as Chief Monetary Officer,” Vaxxas Chief Govt Officer David Hoey mentioned. “Doug’s intensive expertise spans extensive geographical areas, numerous market sectors, and sophisticated regulatory environments, which brings great worth as we commercialize our vaccination know-how platform.”
Vaxxas Chief Monetary Officer Doug Cubbin added, “The chance Vaxxas has to introduce a novel resolution to conventional vaccination strategies is extremely thrilling. I’m thrilled to be becoming a member of the enterprise at this important juncture and look ahead to seeing the corporate proceed to develop as we work in the direction of bringing our first vaccination patch to market.”
Doug’s appointment follows the recruitment to Vaxxas of Scott Fry as Chief Working Officer and Daniel Devine as Chief Enterprise Officer and Basic Counsel, earlier this yr. Scott and Daniel joined Vaxxas from Ellume Restricted and Mesoblast Restricted, respectively.
Vaxxas continues to expertise vital development and at present employs over 110 individuals. To help this development, Vaxxas will transfer right into a state-of-the-art manufacturing facility being constructed by the Queensland Authorities in Brisbane in early 2023.
About Vaxxas’ HD-MAP know-how
The corporate’s proprietary HD-MAP technology platform makes use of an ultra-high-density array of projections – invisible to the bare human eye – utilized to the pores and skin as a patch sitting inside a small applicator gadget. When utilized to the pores and skin, the patch delivers vaccine to the considerable immune cells instantly beneath the pores and skin floor. This strategy has the potential to boost the effectivity and effectiveness of ensuing immune responses of vaccines.
Vaxxas makes use of proprietary dry-coating know-how to use an energetic and steady vaccine onto the projections which gives the potential to eradicate the necessity for vaccine refrigeration throughout storage and transportation – decreasing the useful resource and logistics burden of sustaining the refrigerated “chilly chain”. Ease of use of the HD-MAP may allow simplified administration, doubtlessly encompassing self-administration.
Vaxxas’ HD-MAP is coated with a vaccine candidate and built-in right into a single-use applicator, ready-for-vaccination. All vaccine candidates utilized to the Vaxxas HD-MAP are designed to be efficient and easy-to-use, whereas assembly industrial-scale manufacturing and business logistics necessities.
In intensive laboratory testing revealed in PLoS Med, Vaxxas’ HD-MAP delivered vaccines have proven to be steady and stay energetic when saved and transported at room temperature and exhibit potential for a decrease dose when in comparison with needle and syringe supply of vaccine antigens. Vaxxas has accomplished three human scientific research with its HD-MAP involving greater than 300 members, demonstrating enhanced immune response of vaccine administration by HD-MAP.
About Vaxxas
Vaxxas is a privately held biotechnology firm targeted on enhancing the efficiency of present and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is concentrating on preliminary purposes in infectious illness and oncology.
A Part I scientific examine of a COVID-19 vaccine candidate on a patch is at present underway. Vaxxas can be getting ready for scientific analysis below contract with the US Biomedical Superior Analysis and Growth Authority (BARDA) on pandemic vaccination options.
Vaxxas’ core know-how was initially developed at The College of Queensland (UQ), and the corporate was established as a start-up in 2011 by UQ’s commercialization firm UniQuest. The corporate was based with the completion of an preliminary fairness financing led by OneVentures Innovation Fund I with co-investors Brandon Capital Companions, Brandon BioCatalyst, and US-based HealthCare Ventures, adopted by an extra financing led by OneVentures. OneVentures Innovation Fund I and Brandon BioCatalyst are supported by the Australian Authorities’s Innovation Funding Fund (IIF) program. The IIF is an Australian Authorities enterprise capital initiative that gives funding capital and managerial experience by way of licensed enterprise capital fund managers to investee corporations. Study extra at www.one-ventures.com and www.brandoncapital.vc.
Disclaimer
Vaxxas’ HD-MAP delivered vaccines are below investigation and accessible just for investigational makes use of. They aren’t accessible wherever on the earth on the market or buy. As such, Vaxxas makes no declare that the vaccines are dependable, sturdy, reliable, protected or efficient, and makes no declare that it’s superior to another vaccine or vaccine supply know-how.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20221201005409/en/
Contacts
For media enquiries, please contact:
In Australia:
Amy Miller
WE Communication
+61 431 072 422
amymi@we-worldwide.com
In United States:
Kathryn Morris
The Yates Community
+1 914 204 6412
kathryn@theyatesnetwork.com
